Please login to the form below
Lilly Neuroscience
This page shows the latest Lilly Neuroscience news and features for those working in and with pharma, biotech and healthcare.
Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
Matt Sause, chief executive officer of Roche Diagnostics, said: “We are excited to be collaborating with Lilly on such an important area of unmet medical need. ... Mark Mintun, Lilly group vice president – neuroscience R&D and president, Avid
Latest news
-
Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
Eli Lilly (Lilly) has announced that its experimental Alzheimer’s drug, donanemab, has not been granted accelerated approval by the US Food and Drug Administration (FDA) due to the company not ... Anne White, executive vice president and president of
-
Eli Lilly launches the Institute for Genetic Medicine and a $700m facility investment
Eli Lilly have revealed its plans to launch the Lilly Institute for Genetic Medicine alongside an investment of around $700m. ... The New York site is expected to expand to include up to 200 scientists, all employed by Eli Lilly.
-
Lilly restructures in preparation for Alzheimer’s drug launch
As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration. ... Following the approval of Biogen’s
-
Lilly posts higher-than-expected profit as new drugs lift outlook
diabetes, oncology, immunology and neuroscience,” said David Ricks, Lilly's chairman and CEO. ... Looking forward to 2020, Lilly now expects sales of at least $23.7bn, an increase on previous guidance of $23.6bn.
-
Eli Lilly shutters UK neuroscience unit, with 80 job losses expected
Company says decision is not related to Brexit. Eli Lilly has said it plans to shut down its Windlesham research centre in Surrey, UK, which focused on neuroscience R&D, but ... It also said shifting the neuroscience projects to the US will make it
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Interview: Mike Hutton, Lilly
Nevertheless, unlike some of its peers Lilly has been clear and unwavering in its long-term commitment to neuroscience research. ... It's at this leafy, Surrey site that I met Lilly's chief scientific officer for neurodegenerative diseases Dr Mike Hutton
-
Interview: Jan Lundberg, Eli Lilly
We talk to Jan Lundberg, executive VP, science and technology, and president, Lilly Research Laboratories. ... These priorities could be seen in Lilly's own development plans, Lundberg continued, stating that the company had three products each in
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Create Health
A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
